Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorUdovicich, Cristian-
dc.contributor.authorPerera, Marlon-
dc.contributor.authorHofman, Michael S-
dc.contributor.authorSiva, Shankar-
dc.contributor.authorDel Rio, Andres-
dc.contributor.authorMurphy, Declan G-
dc.contributor.authorLawrentschuk, Nathan-
dc.identifier.citationProstate international 2017; 5(4): 125-129en
dc.description.abstractThe early and accurate detection of prostate cancer is important to ensure timely management and appropriate individualized treatment. Currently, conventional imaging has limitations particularly in the early detection of metastases and at prostate-specific antigen (PSA) levels < 2.0 ng/mL. Furthermore, disease management such as salvage radiotherapy is best at low PSA levels. Thus, it is critical to capture the disease in the oligometastatic stage as disease progression and commencement of systemic therapies can be delayed by metastasis-directed therapy. Prostate-specific membrane antigen (PSMA) is overexpressed in prostatic cancer cells. Novel imaging modalities using radiolabeled tracers with PSMA such as 68Ga-PSMA-positron emission tomography (PET)/computed tomography (CT) have shown promising results. We review the literature regarding 68Ga-PSMA-PET/CT in the setting of primary prostate cancer and biochemical recurrence. At present, the best utilization of 68Ga-PSMA-PET/CT appears to be in biochemical recurrence. 68Ga-PSMA-PET/CT has high diagnostic accuracy for lymph node metastases and has been shown to have superior detection rates to conventional imaging, especially at low PSA levels. The exact role of 68Ga-PSMA-PET/CT in primary prostate cancer is not yet entirely clear. It has an improved detection rate for smaller lesions and may be able to identify nodal or distant metastatic disease at an earlier stage. While still experimental, there may also be value in combining 68Ga-PSMA-PET to multiparametric magnetic resonance imaging for staging of intraprostatic disease. To date, 68Ga-PSMA-PET/CT has been shown to have considerable clinical value and to impact treatment selection for patients with prostate cancer. Still in its infancy, the results of future clinical trials will be excitedly awaited.en
dc.subjectBiochemical recurrenceen
dc.subjectPositron emission tomographyen
dc.subjectProstate canceren
dc.subjectRadical prostatectomyen
dc.title68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends.en
dc.typeJournal Articleen
dc.identifier.journaltitleProstate Internationalen
dc.identifier.affiliationDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Surgery, Mildura Base Hospital, Melbourne, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCentre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Surgery, Western Health, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Surgery, Alfred Health, Melbourne, Australiaen
dc.identifier.affiliationDepartment of Radiology, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.type.austinJournal Article-
dc.type.austinReview- Rio, Andres
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 17, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.